Small Phase I studies have shown ASOs are safe and can reduce aggregated tau. Current Challenges and Clinical Status
Promoting the removal of pathological tau via microglia or through intracellular degradation pathways like the proteasome. Key Therapeutic Strategies antitauon
In the context of neurodegenerative research, "antitauons" refer to or therapeutic agents designed to neutralize tauons —the prion-like, pathological forms of the tau protein that spread from neuron to neuron. Overview of Tauons and Antitauons Small Phase I studies have shown ASOs are
The concept of "tauons" arises from the observation that misfolded tau protein isoforms can propagate through the brain in a characteristic pattern, similar to prions, driving the progression of conditions like Alzheimer's disease. Antitauon therapies aim to intervene in this process through several key mechanisms: similar to prions